BiotechTube

Imsidolimab

Phase 3Terminated
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Generalized Pustular Psoriasis

Conditions

Generalized Pustular Psoriasis

Trial Timeline

Apr 21, 2022 → Jul 17, 2024

NCT ID
NCT05366855

About Imsidolimab

Imsidolimab is a phase 3 stage product being developed by Vanda Pharmaceuticals for Generalized Pustular Psoriasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05366855. Target conditions include Generalized Pustular Psoriasis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT05366855Phase 3Terminated
NCT03619902Phase 2Completed

Competing Products

20 competing products in Generalized Pustular Psoriasis

See all competitors
ProductCompanyStageHype Score
atomoxetine + placeboEli LillyPhase 2/3
65
SatralizumabChugai PharmaceuticalPhase 3
77
PerampanelEisaiPre-clinical
23
Perampanel + Placebo comparatorEisaiPhase 3
77
zonisamideEisaiPre-clinical
23
FycompaEisaiPre-clinical
23
FycompaEisaiPre-clinical
23
PerampanelEisaiPhase 3
77
PerampanelEisaiPre-clinical
23
CenobamateOno PharmaceuticalPhase 3
77
Duloxetine + PlaceboEli LillyPhase 3
77
Duloxetine + PlaceboEli LillyApproved
85
IxekizumabEli LillyApproved
85
eszopiclone + eszopiclone + PlaceboSumitomo PharmaPhase 2
52
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved
85
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)AbbViePhase 2
52
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/dayAbbViePhase 2
52
ABBV-932 + PlaceboAbbViePhase 1
33
EscitalopramAbbVieApproved
85
AdalimumabAbbViePhase 3
77

Other Products from Vanda Pharmaceuticals

tasimelteon 20 mg capsule + tasimelteon 2 mg I.V.Approved
77
IloperidoneApproved
77
Iloperidone + PlaceboPhase 3
69
Iloperidone + Ziprasidone + PlaceboPhase 3
69
VEC-162 20 mg + Placebo + VEC-162 50 mgPhase 3
69